
|Videos|August 26, 2021
Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5



























